查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1870997

丙戊酸钠市场依剂型、通路、适应症、给药途径及规格划分－2025-2032年全球预测

Divalproex Sodium Market by Form, Distribution Channel, Indication, Route Of Administration, Dosage Strength - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，丙戊酸钠市场规模将成长至 40.9 亿美元，复合年增长率为 6.48%。

主要市场统计数据
基准年 2024 24.7亿美元
预计年份：2025年 26.3亿美元
预测年份：2032年 40.9亿美元
复合年增长率 (%) 6.48%

本文简要概述了丙戊酸钠的治疗效用、临床应用、製剂注意事项以及对相关人员的策略意义。

丙戊酸钠在现代神经和精神疾病治疗中占据着举足轻重的地位，它将抗惊厥、情绪稳定和偏头痛预防作用集于一身。临床医师和药品目录相关人员通常不仅评估其动态特征，还会考虑製剂差异和给药途径等因素，这些因素会影响药物的耐受性、起效时间和依从性。随着治疗模式的不断发展，人们越来越关注优化给药方案、利用个人化给药系统最大限度地减少不利事件，以及将治疗监测纳入患者诊疗流程。

分析2025年美国新的关税调整将如何影响供应链风险、筹资策略、定价考量与营运韧性

2025年生效的关税调整和贸易政策变化将为整个製药业的供应链规划和成本结构带来新的复杂性。由于丙戊酸钠等产品依赖全球化的活性药物原料药采购和跨司法管辖区的製造地，关税调整可能会影响原材料、包装组件和成品的到岸成本。製造商和采购团队应重新评估供应商合同，考虑近岸外包的机会，并加强紧急时应对计画，以降低成本波动和潜在的供应中断风险。

将製剂形式、分销管道、适应症、给药途径和剂量强度与临床定位和商业化重点联繫起来的详细細項分析

关键细分市场分析揭示了治疗效用和商业策略如何在製剂形式、分销管道、适应症、给药途径和剂量强度等方面相互交织。就剂型而言，市场涵盖胶囊、注射和片剂，其中片剂又细分为缓释性和速释片。了解缓释片和速释片在临床疗效和依从性方面的权衡对于产品定位至关重要，尤其对于旨在控制慢性病和快速缓解症状的产品而言。分销通路趋势包括医院药局、线上药局模式和零售药局。线上平台进一步细分为直接面向消费者的通路和药局电商平台，而零售通路则分为连锁药局和独立药局。每个管道都提供独特的可及性、报销和病人参与机会，这些都会影响促销策略和库存策略。

提供全面的区域情报，解释地缘政治、支付方和分销变数如何影响关键区域的进入、采用和策略。

区域趋势正在塑造美洲、欧洲、中东和非洲以及亚太地区的需求模式、监管预期和竞争行为，每个地区都呈现出独特的战略要务。在美洲，支付者和整合医疗服务网络对药品目录的製定和价格谈判拥有强大的影响力，因此需要强有力的卫生经济学证据和相关人员的参与，以确保优先获得药品。同时，在欧洲和中东部分地区，监管的日益统一和市场一体化，使得药品目录纳入和竞标流程需要高度的合规性和本地化的证据支持。

主要企业和竞争情报：揭示製造商、专业製药公司和供应链合作伙伴如何透过差异化和策略联盟来建立竞争优势

双丙戊酸钠市场的竞争格局由传统品牌产品、成熟的学名药、专业生产商、合约研发生产机构 (CDMO) 以及原料药(API) 供应商共同构成。创新通常源于缓释性的研发、改进的肠外给药方法以及旨在提高产品稳定性和供应可靠性的生产投资。策略差异化往往来自于经临床试验和真实世界数据验证的成熟安全性管理、优异的药物动力学以及更高的患者依从性。

产业领导者可以采取哪些切实可行的策略重点和营运步骤，以增强丙戊酸钠的韧性、差异化优势和临床应用？以下是一些可操作的策略重点和营运步骤，旨在帮助产业领导者提升丙戊酸钠的韧性、差异化优势和临床应用。

寻求巩固其在丙戊酸钠领域地位的行业领导者应采取切实可行的优先事项，整合临床、营运和商业性因素。首先，整合製剂创新和临床证据生成，以检验缓释片的耐受性和依从性优势，同时保留速释片和静脉注射剂型以满足急性用药需求。其次，鑑于贸易政策的变化，应实现供应链多元化并重新评估供应商合同，以降低关税造成的成本波动风险，并增强应对供应中断的能力。

一套严谨的调查方法，说明了用于产生可靠且可操作的研究结果的资料来源、专家访谈、文献审查和分析检验。

本研究整合了同行评审的临床文献、监管指导文件、药物监测报告和上市公司资讯披露，以循证医学视角审视丙戊酸钠。主要研究资料包括对临床专家、采购负责人和供应链经理的结构化访谈，并辅以製剂专利和生产能力趋势分析，以便更好地了解技术发展趋势和生产限制。次要研究资料包括仔细审查治疗指南、药物专论和监管建议，以确保其符合目前的临床标准和安全考量。

总之，这项综合分析强调，在临床、监管和商业策略方面采取综合方法对于维持医疗服务可近性和优化患者疗效至关重要。

总之，丙戊酸钠仍然是一种重要的治疗药物，製剂形式、给药途径和治疗适应症等方面都涉及许多商业和临床考量。不断变化的临床预期、贸易政策的调整以及分销管道的转变，都使得整合製剂创新、供应链韧性和有针对性的证据生成这三者成为必要。将产品开发、监管策略和商业性执行与实际临床需求相结合的相关人员，将更有利于维持药物可近性并改善患者疗效。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 学名药竞争加剧，导致丙戊酸钠缓释製剂的价格下降，利润空间受到挤压。
  • 扩大数位治疗平台在远端监测接受丙戊酸钠治疗的癫痫患者的应用
  • 由于新的真实世界证据表明丙戊酸钠具有情绪稳定作用，其在双相情感障碍治疗中的应用正在扩大。
  • 丙戊酸钠治疗肝臟安全监测要求的不断变化导致监管力度加大
  • 推出新型每日一次缓释性丙戊酸钠片，以提高病患的依从性和便利性。
  • 远距远端医疗在农村市场的普及，提高了患者获得丙戊酸钠治疗癫痫的途径。
  • 儿童患者安全措施着重于优化丙戊酸钠治疗儿童癫痫的剂量指南。
  • 将药物基因组学检测纳入考量，以调整丙戊酸钠剂量并最大限度地减少药物不良反应。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 丙戊酸钠市场按剂型划分

  • 胶囊
  • 注射
  • 药片
    • 缓释片
    • 速效片

9. 丙戊酸钠市场按分销管道划分

  • 医院药房
  • 网路药房
    • 直接面向消费者的销售平台
    • 面向药局的电子商务平台
  • 零售药房
    • 连锁药局
    • 独立药房

10. 丙戊酸钠市场依适应症划分

  • 躁郁症
  • 癫痫
  • 预防偏头痛

11. 丙戊酸钠市场依给药途径划分

  • 静脉注射
  • 口服

第十二章 丙戊酸钠市场（依浓度划分）

  • 125mg
  • 250mg
  • 500mg

第十三章 丙戊酸钠市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 丙戊酸钠市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国丙戊酸钠市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Limited
    • Aurobindo Pharma Limited
    • Cipla Limited
    • Fresenius Kabi AG
    • Hetero Drugs Limited
Product Code: MRR-1A1A064C0549

The Divalproex Sodium Market is projected to grow by USD 4.09 billion at a CAGR of 6.48% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.47 billion
Estimated Year [2025] USD 2.63 billion
Forecast Year [2032] USD 4.09 billion
CAGR (%) 6.48%

Concise foundational overview presenting the therapeutic utility, clinical context, formulation considerations, and strategic implications for divalproex sodium stakeholders

Divalproex sodium occupies a pivotal position in contemporary therapeutic regimens for a range of neurological and psychiatric disorders, combining antiseizure, mood-stabilizing, and migraine prophylactic properties within a single active pharmaceutical ingredient. Clinicians and formulary stakeholders often evaluate it not only for its pharmacodynamic profile but also for its formulation variants and route-specific considerations that influence tolerability, onset of action, and adherence. As treatment paradigms evolve, attention has shifted toward optimizing dosage regimens, minimizing adverse events through tailored delivery systems, and integrating therapeutic monitoring into patient care pathways.

From a commercial perspective, the product life cycle of divalproex sodium spans originator formulations and a robust generic landscape, with differentiation increasingly driven by extended-release technologies, parenteral options for acute care, and improvements in patient access via diversified distribution channels. Regulatory interactions, safety communications, and evolving clinical guidelines shape prescriber preferences and institutional procurement decisions. Consequently, stakeholders need a concise, evidence-informed introduction that frames clinical utility, formulation strategy, and the competitive environment in a way that supports tactical planning and longer-term portfolio alignment.

Recent years have brought several transformative shifts in the landscape surrounding divalproex sodium that affect clinical practice, manufacturing, and commercial strategy. Advances in formulation technology have enabled more reliable extended-release tablets, reducing peak-related adverse events and improving adherence among patients with chronic indications. Simultaneously, heightened emphasis on inpatient-to-outpatient continuity has increased the importance of intravenous formulations for acute management and stable oral formulations for maintenance therapy, creating a continuum of care that manufacturers and providers must address in a coordinated fashion.

Regulatory frameworks and pharmacovigilance practices are also evolving, pushing manufacturers to invest in post-marketing safety studies and real-world evidence to support product differentiation. Distribution dynamics are shifting as healthcare systems adopt more integrated procurement strategies and as digital platforms expand patient access. These combined forces are driving a re-evaluation of go-to-market strategies, with successful players aligning clinical evidence generation, manufacturing resilience, and distribution flexibility to meet both acute care demands and chronic therapy needs.

Analysis of how new United States tariff adjustments in 2025 reshape supply chain risk, sourcing strategies, pricing considerations, and operational resilience

Tariff changes and trade policy adjustments in the United States in 2025 have introduced new complexities for supply chain planning and cost structuring across the pharmaceutical sector. For products such as divalproex sodium, which rely on globalized active pharmaceutical ingredient sourcing and multi-jurisdictional manufacturing footprints, tariff adjustments can affect the landed cost of raw materials, packaging components, and finished goods. Manufacturers and procurement teams must reassess supplier contracts, evaluate nearshoring opportunities, and strengthen contingency planning to mitigate cost volatility and potential disruptions to supply continuity.

Beyond direct cost implications, tariff shifts can influence strategic decisions about where to locate value-adding activities such as formulation, secondary packaging, and labeling. Companies that proactively realign logistics strategies, diversify supplier bases, and optimize inventory policies are better positioned to absorb short-term tariff shocks while protecting margins and service levels. Regulatory and customs compliance, combined with scenario-based financial modeling, becomes an essential component of commercial planning to preserve access and ensure that clinical needs remain prioritized despite external economic pressures.

In-depth segmentation analysis linking formulations, channels, indications, routes, and dosage strengths to clinical positioning and commercialization priorities

Key segmentation insights reveal how therapeutic utility and commercial strategy intersect across formulation, distribution, indication, route, and dosage strength. In terms of form, the market encompasses capsules, injections, and tablets, with tablets subdivided into extended-release and immediate-release variants; understanding the clinical and adherence trade-offs between extended-release and immediate-release tablets is critical to positioning products for chronic management versus rapid symptom control. Regarding distribution channel dynamics, the landscape includes hospital pharmacy, online pharmacy models, and retail pharmacy outlets, with online platforms further differentiated into direct-to-consumer channels and pharmacy e-commerce platforms and retail channels split between chain and independent pharmacies; each channel presents unique access, reimbursement, and patient engagement opportunities that influence promotional tactics and inventory strategies.

Clinical segmentation by indication spans bipolar disorder, epilepsy, and migraine prophylaxis, requiring tailored medical affairs and commercial narratives that reflect distinct prescriber communities, patient monitoring needs, and evidence requirements. Route of administration considerations cover both intravenous and oral delivery, underscoring the need for acute-care and ambulatory-care strategies that ensure therapeutic continuity. Dosage strength segmentation across 125 mg, 250 mg, and 500 mg formulations speaks to regimen flexibility, titration practices, and inventory planning for varied patient populations. Taken together, these segmentation dimensions should inform cross-functional strategies that align product development, clinical evidence generation, and channel-specific commercialization to maximize therapeutic impact and operational effectiveness.

Comprehensive regional intelligence explaining how geopolitical, payer, and distribution variables in key territories influence access, uptake, and strategy

Regional dynamics shape demand patterns, regulatory expectations, and competitive behavior across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct strategic imperatives. In the Americas, healthcare payers and integrated delivery networks exert strong influence over formulary decisions and pricing negotiations, prompting a need for robust health-economic evidence and stakeholder engagement to secure preferred access. Meanwhile, regulatory consistency and market consolidation in parts of Europe and the Middle East create an environment where formulary inclusion and tendering processes demand high levels of compliance and localized evidence generation.

In the Asia-Pacific region, rapid growth in healthcare infrastructure and varied reimbursement landscapes create both opportunities and complexities for manufacturers, requiring culturally informed market access strategies and flexible distribution models. Across all regions, differences in hospital procurement practices, retail pharmacy structures, and online channel adoption necessitate tailored approaches to distribution, medical education, and post-market surveillance. Companies that craft region-specific regulatory strategies, adapt pricing models to local payer expectations, and invest in targeted clinical and real-world evidence will be best positioned to navigate regional nuances and sustain long-term access.

Key corporate and competitive intelligence highlighting how manufacturers, specialty producers, and supply chain partners create advantage through differentiation and strategic partnerships

Competitive dynamics in the divalproex sodium landscape are shaped by a mix of originator legacy products, established generics, specialty manufacturers, contract development and manufacturing organizations, and API suppliers. Innovation is frequently driven by extended-release formulations, improvements in parenteral delivery, and manufacturing investments that enhance product stability and supply reliability. Strategic differentiation often arises from demonstrated safety management, pharmacokinetic advantages, and proven adherence benefits reflected in clinical studies and real-world outcomes.

Supply chain partnerships and contract manufacturing arrangements play a central role in ensuring continuity of supply, with manufacturers needing to maintain stringent quality oversight and regulatory compliance across global production sites. Commercial success is linked to medical affairs efforts that cultivate prescriber trust, payer engagement that communicates value in clinical and economic terms, and distribution agreements that preserve availability across hospital, retail, and digital channels. Firms that build integrated capabilities across R&D, regulatory strategy, manufacturing, and market access will sustain competitive advantage and create durable customer relationships.

Actionable strategic priorities and operational steps that industry leaders should implement to enhance resilience, differentiation, and clinical engagement for divalproex sodium

Industry leaders seeking to strengthen positions in the divalproex sodium space should adopt a set of actionable priorities that align clinical, operational, and commercial dimensions. First, integrate formulation innovation with clinical evidence generation to validate tolerability and adherence benefits for extended-release tablets while maintaining options for immediate-release and intravenous use in acute settings. Second, diversify supply chains and reassess supplier agreements in light of trade policy changes to reduce exposure to tariff-driven cost fluctuations and to improve resilience against disruptions.

Third, tailor distribution strategies to optimize presence across hospital pharmacies, retail outlets, and online platforms, leveraging direct-to-consumer digital outreach where appropriate while preserving strong relationships with chain and independent pharmacies. Fourth, invest in targeted medical education and health economic evidence that addresses the distinct needs of prescribers managing bipolar disorder, epilepsy, and migraine prophylaxis. Finally, strengthen cross-functional alignment between regulatory affairs, manufacturing, and commercial teams to streamline product lifecycle activities and accelerate responses to safety communications or regulatory changes. These pragmatic steps will support sustained access, improved patient outcomes, and a defensible competitive position.

Robust methodological framework describing data sources, expert interviews, document review, and analytical validation used to produce credible and actionable insights

This research synthesized peer-reviewed clinical literature, regulatory guidance documents, pharmacovigilance reports, and public company disclosures to create an evidence-based perspective on divalproex sodium. Primary input included structured interviews with clinical specialists, procurement professionals, and supply chain managers, supplemented by an analysis of formulation patents and manufacturing capacity signals to understand technology trends and production constraints. Secondary research encompassed careful review of treatment guidelines, drug monographs, and regulatory advisories to ensure alignment with current clinical standards and safety considerations.

Analytical approaches combined qualitative thematic analysis of stakeholder interviews with triangulation from clinical and regulatory sources to validate key conclusions. Scenario planning and sensitivity testing against policy and supply-chain variables were used to explore strategic implications without producing quantitative market projections. Quality assurance steps included cross-validation by subject-matter experts and documentary audits to confirm factual accuracy and relevance. This methodology ensures that recommendations and insights are grounded in a robust synthesis of clinical, regulatory, and operational evidence.

Conclusive synthesis highlighting the imperative for integrated clinical, regulatory, and commercial strategies to sustain access and optimize patient outcomes

In conclusion, divalproex sodium remains an essential therapeutic agent with multifaceted commercial and clinical considerations that extend across formulations, routes of administration, and therapeutic indications. The combined pressures of evolving clinical expectations, trade policy changes, and shifting distribution behaviors necessitate an integrated approach that balances formulation innovation, supply chain resilience, and targeted evidence generation. Stakeholders who align their product development, regulatory strategy, and commercial execution with real-world clinical needs will be better positioned to sustain access and improve patient outcomes.

Moving forward, organizations should prioritize cross-functional planning, invest in regionally tailored market access initiatives, and build stronger linkages between medical affairs and commercial teams to communicate value effectively to prescribers and payers. By doing so, manufacturers and partners can navigate external disruptions while continuing to deliver dependable therapeutic options for patients managing bipolar disorder, epilepsy, and migraine prophylaxis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising competition from generics driving price erosion and profit margin pressures for divalproex sodium extended release formulations
  • 5.2. Increasing adoption of digital therapeutic platforms for remote monitoring of epilepsy patients on divalproex sodium
  • 5.3. Expansion of divalproex sodium use in bipolar disorder based on new real-world evidence on mood stabilization outcomes
  • 5.4. Regulatory scrutiny intensifies as hepatic safety monitoring requirements evolve for divalproex sodium therapy
  • 5.5. Emergence of novel once-daily extended-release divalproex sodium tablets to improve patient adherence and convenience
  • 5.6. Telemedicine-facilitated prescription growth in rural markets enhances access to divalproex sodium for seizure management
  • 5.7. Pediatric patient safety initiatives focus on optimized dosing guidelines for divalproex sodium in childhood epilepsy
  • 5.8. Integration of pharmacogenomic testing to tailor divalproex sodium dosing and minimize adverse drug reactions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Divalproex Sodium Market, by Form

  • 8.1. Capsules
  • 8.2. Injection
  • 8.3. Tablets
    • 8.3.1. Extended Release Tablets
    • 8.3.2. Immediate Release Tablets

9. Divalproex Sodium Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
    • 9.2.1. Direct To Consumer Platform
    • 9.2.2. Pharmacy E-Commerce Platform
  • 9.3. Retail Pharmacy
    • 9.3.1. Chain Pharmacy
    • 9.3.2. Independent Pharmacy

10. Divalproex Sodium Market, by Indication

  • 10.1. Bipolar Disorder
  • 10.2. Epilepsy
  • 10.3. Migraine Prophylaxis

11. Divalproex Sodium Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Divalproex Sodium Market, by Dosage Strength

  • 12.1. 125 Mg
  • 12.2. 250 Mg
  • 12.3. 500 Mg

13. Divalproex Sodium Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Divalproex Sodium Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Divalproex Sodium Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
    • 16.3.3. Viatris Inc.
    • 16.3.4. Sandoz International GmbH
    • 16.3.5. Sun Pharmaceutical Industries Ltd.
    • 16.3.6. Dr. Reddy's Laboratories Limited
    • 16.3.7. Aurobindo Pharma Limited
    • 16.3.8. Cipla Limited
    • 16.3.9. Fresenius Kabi AG
    • 16.3.10. Hetero Drugs Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIVALPROEX SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DIVALPROEX SODIUM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DIVALPROEX SODIUM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIVALPROEX SODIUM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIVALPROEX SODIUM MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIVALPROEX SODIUM MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DIRECT TO CONSUMER PLATFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DIRECT TO CONSUMER PLATFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DIRECT TO CONSUMER PLATFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DIRECT TO CONSUMER PLATFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DIRECT TO CONSUMER PLATFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DIRECT TO CONSUMER PLATFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY PHARMACY E-COMMERCE PLATFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY PHARMACY E-COMMERCE PLATFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY PHARMACY E-COMMERCE PLATFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY PHARMACY E-COMMERCE PLATFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY PHARMACY E-COMMERCE PLATFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY PHARMACY E-COMMERCE PLATFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 125 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 125 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 125 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 125 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 125 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 125 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 250 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 250 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 250 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 250 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 250 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 250 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 500 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 500 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 500 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 500 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 500 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 500 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 307. GCC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 310. GCC DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 311. GCC DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 312. GCC DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 313. GCC DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. GCC DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. GCC DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 316. GCC DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 317. GCC DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 318. GCC DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 319. GCC DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 320. GCC DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 321. GCC DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. GCC DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. GCC DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 324. GCC DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION DIVALPROEX SODIUM MARKET SIZE, BY INDICATI